Ebglyss (lebrikizumab or lebrikizumab-lbkz) is an injectable medication that’s used to treat moderate-to-severe eczema. It’s approved for people 12 years of age and older who weigh at least 88 lbs. This medication is an interleukin-13 antagonist, which works to reduce swelling and discomfort of the skin caused by eczema. Ebglyss (lebrikizumab) is used when topical products aren’t working well enough or when you can’t use them at all. Some people have had side effects like pink eye and pain around the injection site while using Ebglyss (lebrikizumab).
Moderate-to-severe eczema
Ebglyss (lebrikizumab) is a type of monoclonal antibody called an interleukin-13 (IL-13) antagonist. It blocks a protein in your body called IL-13, which plays a role in causing eczema. By blocking IL-13, Ebglyss (lebrikizumab) helps to decrease swelling and irritation in the skin.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Can use with or without topical corticosteroids
Approved for eczema in certain children 12 years of age and older who weigh at least 88 pounds
Injected once every two or four weeks
Must inject under the skin
Can increase the risk of pink eye
Can’t get any live vaccines during treatment
You can inject Ebglyss (lebrikizumab) yourself or have a caregiver help you. But both of you must get trained by a healthcare professional first. They’ll teach you how to safely inject the medication under the skin.
Inject Ebglyss (lebrikizumab) under the skin in your stomach, thigh, or upper arm. If you use your upper arm, have someone help you inject it. Rotate injection sites to avoid scarring and discomfort. You can use the same general area on your body, but don’t put the needle in the same spot every time.
Follow the dosing schedule for your Ebglyss (lebrikizumab) injections. You can use a calendar reminder or alarm to help remember when your injections are. If you miss a dose, inject it as soon as you remember. Then, inject your next dose that’s on your regular schedule.
Some people can have swelling, redness, or warmth at the injection site within a few hours after using Ebglyss (lebrikizumab). This usually goes away within 1 to 2 days. Try using warm compresses, ice packs, and over-the-counter pain medications to relieve symptoms. If your symptoms worsen after a day, tell your prescriber.
You can use Ebglyss (lebrikizumab) with or without topical corticosteroids. You can also use topical calcineurin inhibitors, like tacrolimus (Protopic), on sensitive areas like the face, neck, and genitals.
Tell your primary care provider and pharmacist if you plan on getting any vaccines while taking Ebglyss (lebrikizumab). This medication can change your immune response to some vaccines. Avoid live vaccines while you’re taking Ebglyss (lebrikizumab) since you might be more likely to get sick from the vaccine.
Store Ebglyss (lebrikizumab) in the refrigerator and keep it in its original carton to protect it from light. Don’t freeze or shake it. If needed, you can also store it at room temperature (up to 86°F) for up to 7 days before you have to throw it away.
How to inject Ebglyss (lebrikizumab) using the prefilled pen
Make sure the pen is locked. When you’re ready, uncap the pen by twisting off the gray base cap.
Place and hold the clear base flat against your skin. Then, unlock the pen. With the pen still against your skin, press and hold the purple injection button for 15 seconds. Listen for two loud clicks before removing it from your skin. The first click tells you that the injection started and the second one means that it’s complete.
After each injection, throw the used pen away in a sharps container or an appropriate household container to prevent injuries.
How to inject Ebglyss (lebrikizumab) using the prefilled syringe
Before you inject, let the syringe sit out at room temperature for 45 minutes. Don’t microwave it, run it under hot water, or leave it in direct sunlight to warm it up. This could damage the medication.
When you’re ready, hold the syringe in the middle and pull the needle cap straight off. Gently pinch a fold of skin with one hand and insert the needle at a 45° angle with your other hand. Relax the pinch once the needle is fully into the skin. Then, push the plunger all the way down to inject the medication.
Let go of the plunger until the needle is completely hidden by the shield. You can press a cotton ball to the area where you injected the medication if you see blood (don’t rub the skin).
After each injection, throw the used syringe away in a sharps container or an approved household container. Sharps containers protect people from accidental needle sticks.
Ebglyss (lebrikizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Swelling of the face, lips, or tongue have occurred after taking Ebglyss (lebrikizumab). Some people have also experienced hives. Stop taking Ebglyss (lebrikizumab) and seek help if you notice any of these reactions.
Studies showed that the risk of pink eye was higher in people taking Ebglyss (lebrikizumab) than those who weren’t taking any medication. These cases included both allergic and bacterial pink eye during the first 4 months of treatment. Other people also reported inflammation of the cornea, with symptoms like eye redness and pain. Most times, these eye problems were mild or moderate and went away on their own. Let your primary care provider know about any new or worsening eye symptoms to prevent permanent damage.
Ebglyss (lebrikizumab) wasn’t tested in people with parasitic (worm) infections. So, we don’t know if this medication will change how your immune system fights these infections.
Before starting Ebglyss (lebrikizumab), make sure any parasitic infections are treated. If you get a parasitic worm infection while taking this medication, let your prescriber know so you can start treatment to kill the bug. If the infection doesn’t go away, you’ll probably have to stop using Ebglyss (lebrikizumab) until it clears up.
Avoid getting any live vaccines right before starting treatment and also while taking Ebglyss (lebrikizumab). Live vaccines contain weakened germs, which your body can normally fight. But Ebglyss (lebrikizumab) can weaken your immune response, which can increase your risk of infection from live vaccines.
Tell your primary care provider that you’re taking Ebglyss (lebrikizumab) before getting any vaccines. Even though you can’t get live vaccines, you may still be able to get some other vaccines. This includes the flu shot that’s injected into the muscle.
You’ll typically follow a dosing schedule below:
Week 0 (when you start the medication): The dose is two 250 mg injections (500 mg) under your skin once.
Week 2: The dose is two 250 mg injections (500 mg) under your skin once.
Weeks 4 through 16 (or until symptoms are controlled): The dose is one 250 mg injection under your skin every two weeks.
The following weeks (maintenance): The dose is one 250 mg injection under your skin every four weeks.
Moderate-to-severe eczema - for people 6 months and older
Moderate-to-severe asthma - add-on maintenance for people 6 years and older
Long-term sinus congestion with nasal polyps - add-on maintenance for people 12 years and older
Eosinophilic esophagitis - for people 1 year and older
Prurigo nodularis (long-term itchy skin bumps) - for adults
Chronic obstructive pulmonary disease (COPD) - add-on maintenance for adults
Long-term hives - for people 12 years and older
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
Bieber, T. (2019). Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy.
Centers for Disease Control and Prevention. (n.d.). Conjunctivitis (pink eye).
Centers for Disease Control and Prevention. (2024). About parasites.
Eli Lilly and Company. (2024). Ebglyss- lebrikizumab-lbkz injection, solution [package insert]. DailyMed.
Eli Lilly and Company. (2024). Instructions for use: Ebglyss™ [EHB-glihs] (lebrikizumab-lbkz) injection, for subcutaneous use single-dose prefilled pen.
Eli Lilly and Company. (2024). Instructions for use: Ebglyss™ [EHB-glihs] (lebrikizumab-lbkz) injection, for subcutaneous use single-dose prefilled syringe with needle shield.
National Eczema Society. (n.d.). Topical steroids.
National Eye Institute. (2024). Pink eye.
Schleehauf, B. (2024). How to treat eczema during pregnancy. American Academy of Dermatology Association.
Silverberb, J. I., et al. (2023). Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. The New England Journal of Medicine.
U.S. Department of Health and Human Services. (2022). Vaccine types.
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
Wollenberg, A., et al. (2012). Long term treatment concepts and proactive therapy for atopic eczema. Annals of Dermatology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.